Expiration date: 10/2026
The composition and form of issue:
Tablets, film-coated. 1 tablet contains:
chondroitin sulfate sodium 500 mg
glucosamine hydrochloride 500 mg
excipients: calcium phosphate disodium microcrystalline magnesium stearate stearic acid croscarmellose sodium hydroxypropyl methylcellulose titanium dioxide (E171) triacetin
in polyethylene bottles to 30 or 60 pieces per cardboard pack 1 bottle.
Description pharmaceutical form:
Biconvex tablets are oval, film-coated from white to almost white, engraved with "ARTRA" on the one hand tablets, with a sweet-salty taste and peculiar smell.
View pills on the fault line: the outer layer — the shell is white to almost white inner layer — granular mass of white, with small crystalline inclusions.
Pharmacological action:
Glucosamine and chondroitin sulfates are involved in the biosynthesis of connective tissue, prevent processes of destruction of cartilage and stimulate the regeneration of cartilage tissue.
Pharmacokinetics:
The bioavailability of glucosamine is 25% (pronounced effect "first passage" through the liver). In its distribution in tissues the highest concentrations found in liver, kidney and articular cartilage. About 30% of the dose long persistiruut in bone and muscle tissue. T1/2 of 68 h. write mainly with urine in an unmodified form, partly in the feces.
The bioavailability of chondroitin sulfate — 13%.
Description pharmacological action:
Glucosamine increases the production of cartilage matrix and provides nonspecific protection of cartilage from chemical damage, including caused by NSAIDs and corticosteroids, has a moderate anti-inflammatory effect.
Chondroitin sulfate sodium is an additional substrate for the formation of the cartilage matrix. Stimulates formation of hyaluronan synthesis proteoglycans and type II collagen, protects hyaluronan from enzymatic degradation (by inhibiting the activity of hyaluronidase) and from the damaging effects of free radicals supports the viscosity of synovial fluid, stimulates cartilage repair mechanisms and inhibits the activity of enzymes (elastase, hyaluronidase), destroys the cartilage. Relieves symptoms of osteoarthritis and reduce the need for NSAIDs. Stable therapeutic effect is achieved when taken at least 6 months.
Clinical pharmacology:
The efficacy and safety of ARTRA drug proven multi-center clinical studies conducted on the basis of a number of leading rheumatology clinics of Russia. These studies have shown that treatment with the drug ARTRA in patients with osteoarthritis significantly reduces pain and stiffness in the affected joints, improving their mobility (improvement of more than 90% of patients). More than half of patients on the background of drug treatment (60%) were able to completely stop taking painkillers and anti-inflammatory drugs, without which they could not do before. It is established that ARTRA has a long residual effect (minimum 3 months) — upon completion of the course of treatment in patients with a tendency to a further improvement of the affected joints. Portability ARTRA was very good.
Indications:
Osteoarthritis of the peripheral joints and spine.
Contraindications:
Hypersensitivity expressed by the human kidney.
Application of pregnancy and breast-feeding:
Not recommended during pregnancy. At the time of treatment should stop breastfeeding.
Side effects:
Glucosamine: dysfunction of the gastrointestinal (pain in epigastria, flatulence, diarrhea/constipation), allergic skin reactions.
Chondroitin: allergic reactions.
Drug interactions:
Increases removals tetracycline, reduces the effects of semisynthetic penicillins. Working with NSAIDs and corticosteroids.
Method of application and dose:
Inside, adults and children over 15 years — 1 table. 2 times a day for the first 3 weeks, then 1 table. 1 time per day during the subsequent weeks and months. Stable therapeutic effect is achieved when taken at least 6 months.
Overdose:
Cases overdose unknown.
Treatment: gastric lavage, symptomatic therapy.
